A One Visit Follow Up of Adults With Fabry Disease Who Started Long-term Enzyme Replacement Therapy As Children
NCT04002531 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 5
Last updated 2026-03-04
Summary
The objective of this study is to obtain follow up data on a cohort of well-studied patients with Fabry disease who have been on ERT since childhood for a total of about 15 years.
Conditions
- Quality of Life
- Renal Insufficiency
- Cardiac Event
Interventions
- OTHER
-
General and Neurological examination
Information about your general health, neurological symptoms and current medications with be collected
- OTHER
-
Vital signs
Height, weight, blood pressure, heart rate, and respiratory rate and temperature will be measured.
- PROCEDURE
-
12 lead electrocardiogram
A non-invasive test that measures the electrical activity of the heart
- PROCEDURE
-
Echocardiogram
A non-invasive sonogram of the heart
- PROCEDURE
-
Blood draw
Blood will be drawn to evaluate general health and renal function (kidney health)
- PROCEDURE
-
Urine collection
Urine will be collection to evaluate renal function (kidney health)
- PROCEDURE
-
2-hour Holter Monitor
A non-invasive test that measures the electrical activity of the heart continuously over 2 hours
- OTHER
-
Brief Pain Inventory questionnaire
A questionnaire about daily pain
- OTHER
-
Quality of Life questionnaire
A questionnaire about the impact of disease on their activities of daily living and quality of life
Sponsors & Collaborators
-
Shire
collaborator INDUSTRY -
Baylor Research Institute
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- OTHER
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-11-10
- Primary Completion
- 2019-12-13
- Completion
- 2019-12-13
Countries
- United States
Study Locations
More Related Trials
-
Study of the Quality of Life of Patients With Fabry Disease Aged 65 and Over With and Without Specific Treatment
NCT07277361 ·Status: RECRUITING
-
A Study of Fabrazyme in Pediatric Patients With Fabry Disease
NCT00074958 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy Study of Several Replagal Dosing Regimens on Cardiac Function in Adults With Fabry Disease
NCT00864851 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Enzyme Replacement Therapy in Patients With Fabry Disease
NCT06880250 ·Status: ENROLLING_BY_INVITATION
-
A Study to Assess the Safety and Tolerability of Lucerastat in Subjects With Fabry Disease
NCT02930655 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease
NCT01218659 ·Status: COMPLETED ·Phase: PHASE3
-
A Multicenter Open-Label Treatment Protocol to Observe the Safety of Replagal (Agalsidase Alfa) Enzyme Replacement Therapy in Canadian Patients With Fabry Disease
NCT01298141 ·Status: COMPLETED ·Phase: PHASE3
-
A Long Term Safety and Efficacy Study of Fabrazyme Replacement Therapy in Japanese Patients With Fabry Disease.
NCT00233870 ·Status: COMPLETED
-
Characterisation of Heart Involvement in Fabry Disease With T1 Mapping
NCT04708301 ·Status: COMPLETED
-
Inflammatory Pathways and Cardiac Growth Factors Associated With Fabry Disease Cardiomyopathy
NCT04724083 ·Status: UNKNOWN
-
Safety Study of Replagal® Therapy in Children With Fabry Disease
NCT01363492 ·Status: COMPLETED ·Phase: PHASE2
-
Open-Label Expanded Access Treatment With Pegunigalsidase Alfa for Fabry Disease Patients
NCT04552691 ·Status: APPROVED_FOR_MARKETING
-
A Long Term Follow-Up Study of Fabry Disease Subjects Treated With FLT190
NCT04455230 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Extension Study of TKT028 Evaluating Safety and Clinical Outcomes of Replagal® in Adult Patients With Fabry Disease
NCT01124643 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of Efficacy and Safety of Agalsidase Beta in Heterozygous Females for Fabry Disease
NCT00487630 ·Status: UNKNOWN ·Phase: PHASE4
-
Enzyme Replacement Therapy in Fabry Disease
NCT00149318 ·Status: TERMINATED
-
A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe Symptoms
NCT00701415 ·Status: COMPLETED ·Phase: PHASE3
-
Biomarkers and Cardiac Imaging Diagnostic Assay for Monitoring Patients With Fabry Disease
NCT05698901 ·Status: RECRUITING
-
German Observational Multicenter Study of Patients With Fabry Disease Under Enzyme Replacement Therapy With Pegunigalsidase-alfa
NCT06095713 ·Status: ACTIVE_NOT_RECRUITING
-
A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease
NCT00074971 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Patients With Fabry Disease (US Specific)
NCT06906367 ·Status: RECRUITING
-
Agalsidase Beta Long-Term Treatment Outcome for Fabry Disease Patients With IVS4 Mutation in Taiwan
NCT06052800 ·Status: ACTIVE_NOT_RECRUITING
-
China Post-marketing Surveillance (PMS) Study of Fabrazyme®
NCT05054387 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluation of the Long-term Safety, Pharmacodynamics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-Naïve Adult Male Patients With Fabry Disease
NCT02489344 ·Status: COMPLETED ·Phase: PHASE2
-
Home Therapy With Replagal in Fabry Disease
NCT01355146 ·Status: COMPLETED